Speaker Profile
Ph.D., Director, Cancer Genome Analysis & Professor of Pathology, MGH & Broad Inst.
Biography
Dr. Getz is an internationally acclaimed leader in cancer genomics and is pioneering widely used tools for analyzing cancer genomes. Dr. Getz is a Professor of Pathology at Harvard Medical School. He is the Director of Bioinformatics at the Massachusetts General Hospital (MGH) Cancer Center and Department of Pathology, and is an Institute Member of the Broad Institute of MIT and Harvard, where he directs the Cancer Genome Computational Analysis Group. He has published over 400 papers in prominent journals describing new methodologies to study cancer genomes that have identified new genes and pathways involved in different tumor types, mutational signatures, and tumor evolution.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Emre Baser, AstraZeneca
PMWC Award Ceremony
• Max Diehn, Stanford (Pioneer)
• Sarah-Jane Dawson, Peter MacCallum Cancer Centre / University of Melbourne (Luminary)
Featured Speakers
• Max Diehn, Stanford
• Sarah-Jane Dawson, University of Melbourne
• Phil Febbo, Veracyte
• Ash Alizadeh, Stanford
• Adrian Lee, University of Pittsburgh
• Emre Baser, AstraZeneca
• Keith Flaherty, Mass General
• Thomas Powles, Barts Cancer Institute
Early-Stage Cancer: Can MRD Decide Who Needs More Treatment?
When ctDNA should change escalation, de-escalation, and surveillance.
Advanced Cancer Monitoring
Detecting response, resistance, and relapse early enough to switch therapy.
From Blood to Drug
Liquid biopsy for therapy selection and matching patients to the right intervention.
Integrating Tissue, Liquid & Imaging Biomarkers
How multimodal monitoring should work in real oncology care.
MRD as a Surrogate Endpoint
The promise and hazards of using MRD to accelerate drug approval.
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
